Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Compassionate Use Study of Leronlimab (PRO 140) in Combination With Treatment of Physician's Choice in Patients With CCR5+ Metastatic Triple Negative Breast Cancer (mTNBC)

Next Previous
Search
Trial Profile

A Compassionate Use Study of Leronlimab (PRO 140) in Combination With Treatment of Physician's Choice in Patients With CCR5+ Metastatic Triple Negative Breast Cancer (mTNBC)

Status: Active, no longer recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 14 Jul 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Leronlimab (Primary) ; Capecitabine; Carboplatin; Eribulin; Gemcitabine; Ixabepilone; Paclitaxel; Vinorelbine
  • Indications Advanced breast cancer; Triple negative breast cancer
  • Focus Expanded access; Therapeutic Use
  • Sponsors CytoDyn

    • Most Recent Events

    • 07 Jun 2022 Results of pooled analysis from NCT03838367, NCT04313075, NCT04504942; exploring the effect of leronlimab on circulating tumor associated cells (TACs) from peripheral blood as a surrogate and early predictor of drug response, presented at the 58th Annual Meeting of the American Society of Clinical Oncolog
    • 13 Apr 2022 Blood sample from 3 studies (NCT03838367, NCT04313075 & NCT04504942) were used to assess the predictive value of TACs, measured by the LifeTracDx assay, presented at the 113th Annual Meeting of the American Association for Cancer Research.
    • 13 Jan 2022 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top